- Home
- DBRG vs IBRX Comparison
DBRG vs IBRX Comparison
Compare DBRG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- IBRX
- Stock Information
- Founded
- DBRG 1991
- IBRX 2014
- Country
- DBRG United States
- IBRX United States
- Employees
- DBRG N/A
- IBRX N/A
- Industry
- DBRG Real Estate Investment Trusts
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBRG Real Estate
- IBRX Health Care
- Exchange
- DBRG Nasdaq
- IBRX Nasdaq
- Market Cap
- DBRG 2.3B
- IBRX 2.3B
- IPO Year
- DBRG 2009
- IBRX N/A
- Fundamental
- Price
- DBRG $12.47
- IBRX $2.46
- Analyst Decision
- DBRG Strong Buy
- IBRX Strong Buy
- Analyst Count
- DBRG 7
- IBRX 6
- Target Price
- DBRG $16.00
- IBRX $9.83
- AVG Volume (30 Days)
- DBRG 3.8M
- IBRX 9.3M
- Earning Date
- DBRG 10-30-2025
- IBRX 11-11-2025
- Dividend Yield
- DBRG 0.32%
- IBRX N/A
- EPS Growth
- DBRG N/A
- IBRX N/A
- EPS
- DBRG N/A
- IBRX N/A
- Revenue
- DBRG $173,540,000.00
- IBRX $56,600,000.00
- Revenue This Year
- DBRG N/A
- IBRX $629.94
- Revenue Next Year
- DBRG $77.07
- IBRX $109.91
- P/E Ratio
- DBRG N/A
- IBRX N/A
- Revenue Growth
- DBRG N/A
- IBRX 4227.22
- 52 Week Low
- DBRG $6.41
- IBRX $1.83
- 52 Week High
- DBRG $17.33
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- DBRG 54.26
- IBRX 49.22
- Support Level
- DBRG $11.71
- IBRX $2.30
- Resistance Level
- DBRG $12.91
- IBRX $2.50
- Average True Range (ATR)
- DBRG 0.82
- IBRX 0.12
- MACD
- DBRG -0.01
- IBRX -0.01
- Stochastic Oscillator
- DBRG 52.62
- IBRX 47.30
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.